First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

Science Translational Medicine

Volumn 8, Issue 370, 2016, Pages

  Borroto, Aldo ^a   Reyes Garau, Diana ^a   Jiménez, M Angeles ^b   Carrasco, Esther ^c   Moreno, Beatriz ^d   Martínez Pasamar, Sara ^d   Cortés, José R ^e   Perona, Almudena ^a   Abia, David ^a   Blanco, Soledad ^a   Fuentes, Manuel ^f   Arellano, Irene ^a   Lobo, Juan ^a   Heidarieh, Haleh ^a   Rueda, Javier ^a   Esteve, Pilar ^a   Cibrián, Danay ^e   Martinez Riaño, Ana ^a   Mendoza, Pilar ^a   Prieto, Cristina ^a   Calleja, Enrique ^a   Oeste, Clara L ^a   Orfao, Alberto ^f   Fresno, Manuel ^a   Sánchez Madrid, Francisco ^e   Alcamí, Antonio ^a   Bovolenta, Paola ^a   Martín, Pilar ^e   Villoslada, Pablo ^d   Morreale, Antonio ^a   Messeguer, Angel ^c   Alarcon, Balbino ^a   more..

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^f UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AX 024; CLADRIBINE; FINGOLIMOD; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; NCK PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL ALLERGIC ENCEPHALITIS; FEMALE; HUMAN; IC50; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PSORIASIS; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; DRUG DESIGN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CYTOKINES; DRUG DESIGN; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOSUPPRESSION; INHIBITORY CONCENTRATION 50; LIGANDS; LYMPHOCYTE ACTIVATION; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; PROTEIN DOMAINS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES;

EID: 85007006461     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf2140     Document Type: Article

References (52)

1. M. M. A. Fernando, C. R. Stevens, E. C. Walsh, P. L. De Jager, P. Goyette, R. M. Plenge, T. J. Vyse, J. D. Rioux, Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLOS Genet. 4, e1000024 (2008).
2. G. P. Morris, P. M. Allen, How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat. Immunol. 13, 121-128 (2012).
3. R. I. Nurieva, X. Liu, C. Dong, Molecular mechanisms of T-cell tolerance. Immunol. Rev. 241, 133-144 (2011).
4. H. von Boehmer, F. Melchers, Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 11, 14-20 (2010).
5. Y. Y. Wan, R. A. Flavell, How diverse-CD4 effector T cells and their functions. J. Mol. Cell Biol. 1, 20-36 (2009).
6. M. D. Rosenblum, I. K. Gratz, J. S. Paw, A. K. Abbas, Treating human autoimmunity: Current practice and future prospects. Sci. Transl. Med. 4, 125sr1 (2012).
7. E. J. Fox, R. W. Rhoades, New treatments and treatment goals for patients with relapsingremitting multiple sclerosis. Curr. Opin. Neurol. 25, S11-S19 (2012).
8. O. Neuhaus, B. C. Kieseier, H.-P. Hartung, Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 4, 654-660 (2007).
9. P. J. Bugelski, R. Achuthanandam, R. J. Capocasale, G. Treacy, E. Bouman-Thio, Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol. 5, 499-521 (2009).
10. P. E. Love, S. M. Hayes, ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harbor Perspect. Biol. 2, a002485 (2010).
11. I. de Aós, M. H. Metzger, M. Exley, C. E. Dahl, S. Misra, D. Zheng, L. Varticovski, C. Terhorst, J. Sancho, Tyrosine phosphorylation of the CD3-e subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells. J. Biol. Chem. 272, 25310-25318 (1997).
12. L. M. DeFord-Watts, J. A. Young, L. A. Pitcher, N. S. C. van Oers, The membrane-proximal portion of CD3 e associates with the serine/threonine kinase GRK2. J. Biol. Chem. 282, 16126-16134 (2007).
13. P. Delgado, B. Cubelos, E. Calleja, N. Martínez-Martín, A. Ciprés, I. Mérida, C. Bellas, X. R. Bustelo, B. Alarcón, Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 10, 880-888 (2009).
14. L. Buday, L. Wunderlich, P. Tamás, The Nck family of adapter proteins: Regulators of actin cytoskeleton. Cell. Signalling 14, 723-731 (2002).
15. M. Lettau, J. Pieper, A. Gerneth, B. Lengl-Janßen, M. Voss, A. Linkermann, H. Schmidt, C. Gelhaus, M. Leippe, D. Kabelitz, O. Janssen, The adapter protein Nck: Role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 19, 658-669 (2010).
16. E. Roy, D. Togbe, A. Holdorf, D. Trubetskoy, S. Nabti, G. Küblbeck, S. Schmitt, A. Kopp-Schneider, F. Leithäuser, P. Möller, F. Bladt, G. J. Hämmerling, B. Arnold, T. Pawson, A. Tafuri, Fine tuning of the threshold of T cell selection by the Nck adapters. J. Immunol. 185, 7518-7526 (2011).
17. E. Roy, D. Togbe, A. D. Holdorf, D. Trubetskoy, S. Nabti, G. Küblbeck, A. Klevenz, A. Kopp-Schneider, F. Leithäuser, P. Möller, F. Bladt, G. Hämmerling, B. Arnold, T. Pawson, A. Tafuri, Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proc. Natl. Acad. Sci. U.S.A. 107, 15529-15534 (2010).
18. D. Gil, W. W. A. Schamel, M. Montoya, F. Sánchez-Madrid, B. Alarcón, Recruitment of Nck by CD3e reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell 109, 901-912 (2002).
19. R. Blanco, A. Borroto, W. Schamel, P. Pereira, B. Alarcon, Conformational changes in the T cell receptor differentially determine T cell subset development in mice. Sci. Signaling 7, ra115 (2014).
20. P. Tailor, S. Tsai, A. Shameli, P. Serra, J. Wang, S. Robbins, M. Nagata, A. L. Szymczak-Workman, D. A. A. Vignali, P. Santamaria, The proline-rich sequence of CD3e as an amplifier of low-avidity TCR signaling. J. Immunol. 181, 243-255 (2008).
21. O. Aitio, M. Hellman, T. Kesti, I. Kleino, O. Samuilova, K. Pääkkönen, H. Tossavainen, K. Saksela, P. Permi, Structural basis of PxxDY motif recognition in SH3 binding. J. Mol. Biol. 382, 167-178 (2008).
22. C. M. Santiveri, A. Borroto, L. Simón, M. Rico, B. Alarcón, M. A. Jiménez, Interaction between the N-terminal SH3 domain of Ncka and CD3e-derived peptides: Non-canonical and canonical recognition motifs. Biochim. Biophys. Acta 1794, 110-117 (2009).
23. K. Takeuchi, H. Yang, E. Ng, S.-y. Park, Z.-Y. Sun, E. L. Reinherz, G. Wagner, Structural and functional evidence that Nck interaction with CD3e regulates T-cell receptor activity. J. Mol. Biol. 380, 704-706 (2008).
24. S. S.-C. Li, Specificity and versatility of SH3 and other proline-recognition domains: Structural basis and implications for cellular signal transduction. Biochem. J. 390, 641-653 (2005).
25. A. M. Mongiovi, P. R. Romano, S. Panni, M. Mendoza, W. T. Wong, A. Musacchio, G. Cesareni, P. P. Di Fiore, A novel peptide-SH3 interaction. EMBO J. 18, 5300-5309 (1999).
26. Á. C. Cabrera, R. Gil-Redondo, A. Perona, F. Gago, A. Morreale, VSDMIP 1.5: An automated structure-and ligand-based virtual screening platform with a PyMOL graphical user interface. J. Comput. Aided Mol. Des. 25, 813-824 (2011).
27. A. Castello, M. Gaya, J. Tucholski, T. Oellerich, K.-H. Lu, A. Tafuri, T. Pawson, J. Wienands, M. Engelke, F. D. Batista, Nck-mediated recruitment of BCAP to the BCR regulates the PI(3) K-Akt pathway in B cells. Nat. Immunol. 14, 966-975 (2013).
28. A. Borroto, I. Arellano, R. Blanco, M. Fuentes, A. Orfao, E. P. Dopfer, M. Prouza, M. Suchànek, W. W. Schamel, B. Alarcón, Relevance of Nck-CD3e interaction for T cell activation in vivo. J. Immunol. 192, 2042-2053 (2014).
29. A. Borroto, I. Arellano, E. P. Dopfer, M. Prouza, M. Suchànek, M. Fuentes, A. Orfao, W. W. Schamel, B. Alarcón, Nck recruitment to the TCR required for ZAP70 activation during thymic development. J. Immunol. 190, 1103-1112 (2013).
30. M. Carducci, L. Perfetto, L. Briganti, S. Paoluzi, S. Costa, J. Zerweck, M. Schutkowski, L. Castagnoli, G. Cesareni, The protein interaction network mediated by human SH3 domains. Biotechnol. Adv. 30, 4-15 (2012).
31. T. Kesti, A. Ruppelt, J.-H. Wang, M. Liss, R. Wagner, K. Taskén, K. Saksela, Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3e. J. Immunol. 179, 878-885 (2007).
32. S. M. Schleicher, Psoriasis: Pathogenesis, assessment, and therapeutic update. Clin. Podiatr. Med. Surg. 33, 355-366 (2016).
33. B. Flutter, F. O. Nestle, TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 43, 3138-3146 (2013).
34. L. van der Fits, S. Mourits, J. S. A. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A.-M. Mus, E. Florencia, E. P. Prens, E. Lubberts, Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845 (2009).
35. H. Korideck, J. D. Peterson, Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. J. Pharmacol. Exp. Ther. 329, 882-889 (2009).
36. B. Bosnjak, B. Stelzmueller, K. J. Erb, M. M. Epstein, Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir. Res. 12, 114 (2011).
37. C. E. Markowitz, Multiple sclerosis update. Am. J. Manag. Care 19, s294-s300 (2013).
38. E. Mix, H. Meyer-Rienecker, H.-P. Hartung, U. K. Zettl, Animal models of multiple sclerosis-Potentials and limitations. Prog. Neurobiol. 92, 386-404 (2010).
39. B. C. Kieseier, D. R. Jeffery, Chemotherapeutics in the treatment of multiple sclerosis. Ther. Adv. Neurol. Disord. 3, 277-291 (2010).
40. C. S. Garris, V. A. Blaho, T. Hla, M. H. Han, Sphingosine-1-phosphate receptor 1 signalling in T cells: Trafficking and beyond. Immunology 142, 347-353 (2014).
41. N. J. Tubo, A. J. Pagán, J. J. Taylor, R. W. Nelson, J. L. Linehan, J. M. Ertelt, E. S. Huseby, S. S. Way, M. K. Jenkins, Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. Cell 153, 785-796 (2013).
42. V. Daniel, H. Wang, M. Sadeghi, G. Opelz, Interferon-g producing regulatory T cells as a diagnostic and therapeutic tool in organ transplantation. Int. Rev. Immunol. 33, 195-211 (2014).
43. V. Panchanathan, G. Chaudhri, G. Karupiah, Correlates of protective immunity in poxvirus infection: Where does antibody stand? Immunol. Cell Biol. 86, 80-86 (2008).
44. G. Chaudhri, V. Tahiliani, P. Eldi, G. Karupiah, Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T celldependent antibody and CD8 T cell responses. J. Virol. 89, 1889-1899 (2015).
45. M. A. Daniels, E. Teixeiro, J. Gill, B. Hausmann, D. Roubaty, K. Holmberg, G. Werlen, G. A. Holländer, N. R. J. Gascoigne, E. Palmer, Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 444, 724-729 (2006).
46. A. M. Bulek, D. K. Cole, A. Skowera, G. Dolton, S. Gras, F. Madura, A. Fuller, J. J. Miles, E. Gostick, D. A. Price, J. W. Drijfhout, R. R. Knight, G. C. Huang, N. Lissin, P. E. Molloy, L. Wooldridge, B. K. Jakobsen, J. Rossjohn, M. Peakman, P. J. Rizkallah, A. K. Sewell, Structural basis for the killing of human b cells by CD8+ T cells in type 1 diabetes. Nat. Immunol. 13, 283-289 (2012).
47. S. Enouz, L. Carrié, D. Merkler, M. J. Bevan, D. Zehn, Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J. Exp. Med. 209, 1769-1779 (2012).
48. S. Koehli, D. Naeher, V. Galati-Fournier, D. Zehn, E. Palmer, Optimal T-cell receptor affinity for inducing autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 111, 17248-17253 (2014).
49. Y. Yoshida, T. Tsuji, T. Fujita, T. Kohno, Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen. Biol. Pharm. Bull. 34, 933-936 (2011).
50. B. B. Au-Yeung, S. E. Levin, C. Zhang, L.-Y. Hsu, D. A. Cheng, N. Killeen, K. M. Shokat, A. Weiss, A genetically selective inhibitor demonstrates a function for the kinase Zap70 in regulatory T cells independent of its catalytic activity. Nat. Immunol. 11, 1085-1092 (2010).
51. D. Weininger, SMILES, a chemical language and information system 1 Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31-36 (1988).
52. R. Gil-Redondo, J. Estrada, A. Morreale, F. Herranz, J. Sancho, A. R. Ortiz, VSDMIP: Virtual screening data management on an integrated platform. J. Comput. Aided Mol. Des. 23, 171-184 (2009).